Revenue grew 12% year-over-year to $161M, driven by Sample Management Solutions and Multiomics. Adjusted EBITDA margin was 11.4%, with FY26 guidance for flat to 1% organic revenue growth and $59–$62M adjusted EBITDA. B Medical Systems sale closed, and $50M in shares were repurchased.Original docume…
Revenue grew 12% year-over-year to $161M, driven by Sample Management Solutions and Multiomics. Adjusted EBITDA margin was 11.4%, with FY26 guidance for flat to 1% organic revenue growth and $59–$62M adjusted EBITDA. B Medical Systems sale closed, and $50M in shares were repurchased.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
